%0 Journal Article %J Biol Blood Marrow Transplant %D 2014 %T Autoimmune hematological diseases after allogeneic hematopoietic stem cell transplantation in children: an Italian multicenter experience. %A Faraci, Maura %A Zecca, Marco %A Pillon, Marta %A Rovelli, Attilio %A Menconi, Maria Cristina %A Ripaldi, Mimmo %A Fagioli, Franca %A Rabusin, Marco %A Ziino, Ottavio %A Lanino, Edoardo %A Locatelli, Franco %A Daikeler, Thomas %A Prete, Arcangelo %K Child %K Child, Preschool %K Female %K Hematologic Diseases %K Hematopoietic Stem Cell Transplantation %K Humans %K Italy %K Male %K Remission Induction %K Risk Factors %K Transplantation Conditioning %X

Autoimmune hematological diseases (AHDs) may occur after allogeneic hematopoietic stem cell transplantation (HSCT), but reports on these complications in large cohorts of pediatric patients are lacking. Between 1998 and 2011, 1574 consecutive children underwent allogeneic HSCT in 9 Italian centers. Thirty-three children (2.1%) developed AHDs: 15 autoimmune hemolytic anemia (45%), 10 immune thrombocytopenia (30%), 5 Evans' syndrome (15%), 2 pure red cell aplasia (6%), and 1 immune neutropenia (3%). The 10-year cumulative incidence of AHDs was 2.5% (95% confidence interval, 1.7 to 3.6). In a multivariate analysis, the use of alternative donor and nonmalignant disease was statistically associated with AHDs. Most patients with AHDs (64%) did not respond to steroids. Sustained complete remission was achieved in 87% of cases with the anti-CD20 monoclonal antibody (rituximab). Four patients (9%) (1 autoimmune hemolytic anemia, 1 Evans' syndrome, 2 immune thrombocytopenia) died at a median of 87 days after AHD diagnosis as a direct or indirect consequence of their disorder. Our data suggest that AHDs are a relatively rare complication occurring after HSCT that usually respond to treatment with rituximab.

%B Biol Blood Marrow Transplant %V 20 %P 272-8 %8 2014 Feb %G eng %N 2 %1 http://www.ncbi.nlm.nih.gov/pubmed/24274983?dopt=Abstract %R 10.1016/j.bbmt.2013.11.014 %0 Journal Article %J Transplantation %D 2011 %T Glutamine-enriched nutrition does not reduce mucosal morbidity or complications after stem-cell transplantation for childhood malignancies: a prospective randomized study. %A Uderzo, Cornelio %A Rebora, Paola %A Marrocco, Emanuela %A Varotto, Stefania %A Cichello, Francesca %A Bonetti, Maurizio %A Maximova, Natalia %A Zanon, Davide %A Fagioli, Franca %A Nesi, Francesca %A Masetti, Riccardo %A Masetti, Roberto %A Rovelli, Attilio %A Rondelli, Roberto %A Valsecchi, Maria Grazia %A Cesaro, Simone %K Adolescent %K Analgesia %K Child %K Child, Preschool %K Double-Blind Method %K Female %K Glutamine %K Hematopoietic Stem Cell Transplantation %K Humans %K Infant %K Male %K Mucositis %K Mucous Membrane %K Neoplasms %K Odds Ratio %K Parenteral Nutrition %K Prospective Studies %K Recurrence %K Stem Cells %K Treatment Outcome %X

BACKGROUND: Intravenous glutamine-enriched solution seems to be effective in posttransplant period in decreasing the severity and duration of mucositis. The aim of this randomized study was to determine the benefit of glutamine supplementation both on mucosal morbidity and in posttransplant associated complications.

METHODS: Children undergoing allogeneic hematopoietic stem-cell transplantation (HSCT) for malignant hematological diseases were randomly assigned to standard total parenteral nutrition (S-TPN) or glutamine-enriched (GE)-TPN solution consisting of 0.4 g/kg/day of l-alanine-glutamine dipeptide. This treatment started on the day of HSCT and ended when the patients could orally cover more than 50% of their daily energy requirements. The severity and the rate of post-HSCT mucositis were based on World Health Organization criteria. All the analyses were conducted on intention-to-treat principle.

RESULTS: One hundred twenty consecutive patients (83 men; median age, 8.1 years) were enrolled. The mean duration of treatment was 23.5 and 23 days in the two treatment arms. The mean calorie intake was 1538 kcal/d in the S-TPN group and 1512 kcal/d in GE-TPN group. All patients were well nourished before and after HSCT. Mucositis occurred in 91.4% and 91.7% of patients in S-TPN and GE-TPN arm, respectively (P=0.98). Odds ratio adjusted by type of HSCT was 0.98 (95% confidence interval, 0.26-2.63). Type and duration of analgesic treatment, clinical outcome (engraftment, graft versus host disease, early morbidity, and mortality, relapse rate up to 180 days post-HSCT) were not significantly different in the two treatment arms.

CONCLUSION: GE-TPN solution does not affect mucositis and outcome in well-nourished HSCT allogeneic patients.

%B Transplantation %V 91 %P 1321-5 %8 2011 Jun 27 %G eng %N 12 %1 http://www.ncbi.nlm.nih.gov/pubmed/21499196?dopt=Abstract %R 10.1097/TP.0b013e31821ab959